News
Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has been increasing in recent years. Currently, diabetics make up approximately 8−10% of the population. The therapy is traditionally focused primarily on suppressing the development and progression of diabetic complications, but modern antidiabetics have also brought other unprecedented benefits. The following text summarizes the role of gliflozins in the pharmacotherapy of DM2 in light of current recommendations.
Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is…
Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The…
Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis
Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on…
Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab
An analysis of results in adult patients with moderate to severe atopic dermatitis, who also had…
Effect of Telmisartan and Losartan on Bone Turnover Markers in Patients with Newly Diagnosed Stage I Hypertension
Telmisartan, an AT1 receptor blocker for angiotensin II and partial agonist of the PPAR-γ receptor,…
The Anti-inflammatory and Renoprotective Effect of Candesartan May Be Independent of the AT1 Receptor
Candesartan belongs to the blockers of AT1 receptors (AT1R) for angiotensin II coupled with G…
Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia
One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells…
Teriflunomide vs. Dimethyl Fumarate in Real Practice: We Know the Winner! Will It Surprise You?
Teriflunomide and dimethyl fumarate are disease-modifying drugs (DMDs) used in the treatment of multiple...
MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?
What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases from...
Conferences
News from the world of medicine
All conferences
Popular this week
- Where did COVID come from? Are infected animals or a lab leak to blame for the pandemic?
- Target blood pressure values in heart failure
- BENIGN DERMATOSIS OF PENIS
- Hypercalcemia may be the first sign of multiple myeloma, but not only that
- Could Artificial Intelligence Help with Emergency Department Triage in the Future?